Psilocybin
Psychedellux June 25, 2021
Psychedelic biotech company Awakn Life Sciences Corp. (NEO: AWKN) began trading on the NEO Exchange Inc. under the symbol “AWKN”. The company has…

Psychedelic biotech company Awakn Life Sciences Corp. (NEO: AWKN) began trading on the NEO Exchange Inc. under the symbol “AWKN”. The company has raised C$13.5 million to date and has plans to open three UK psychedelic-assisted psychotherapy clinics where it will deliver ketamine-assisted therapies near term and MDMA when they secure authorization in 2021. The company’s target is 20 clinics by the end of 2024.
Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) has entered into a non-binding letter of intent to acquire a 51% stake in Acadian Exotic Mushrooms Ltd. AEM is a dormant gourmet mushroom production facility. Upon completion of start-up activities, the 22,000 square foot facility is expected to produce up to 5,000 pounds of Shiitake mushrooms per week. AEM will also have the ability to produce, package and distribute a wide variety of fresh mushrooms while offering an assortment of dried options and the potential to produce functional mushroom consumer packaged goods.
Silo Wellness Inc. (CSE: SILO) (OTC: SILFF) has launched Marley One, a psychedelic mushroom consumer brand, in collaboration with the family of legendary musician Bob Marley. Silo said that the initial product offering will include a range of functional mushroom tinctures with unique blends highlighting the brand’s connection to Jamaica, including species such as cordyceps, lion’s mane, chaga, reishi, and turkey tail. These initial mushroom supplements have no psychoactive properties, but Silo said it is planning a psychedelic mushroom product line under the Marley name later this year.
The post Psychedellux June 25, 2021 appeared first on Green Market Report.
mushroom mdma ketamine psychedelic psychoactive psychotherapy trading cse otc red light holland silo awakn life sciences awakn authorization
-
MDMA22 hours ago
Shifting Strategy, MAPS Turns to Equity Investment
-
Public Companies10 hours ago
Atai CEO Answers Questions From the Public
-
Psilocybin9 hours ago
PSYC’s CEO to Moderate Panel at Film Screening for ESPN’s Upcoming Documentary, “Peace of Mind”
-
Psychedelics3 hours ago
Joël Brierre Calls To Those Seeking Transformation – Podcast Episode #24
-
Public Companies6 hours ago
PharmaTher Announces Positive FDA Meeting; Path Towards Phase 3 Trial
-
MDMA6 hours ago
Massachusetts Republican Wants to Cap Potential MDMA Therapy Costs
-
Psilocybin4 hours ago
Psilocybin Therapies Attract Support in Illinois Legislature